Entheon Biomedical is a biotechnology company committed to the development of safe, legal pathways for patients to access evidence-based addiction treatments and proprietary entheogen based formulations.
Entheon Biomedical is a psychedelic R&D company focused on addressing the lack of treatment options available to those suffering from addictive disorders. Entheogens have a long history in the treatment of addictive disorders. We are working alongside a growing community of scientists and medical professionals to dispel and overcome the many misconceptions with respect to the clinical use of entheogenic substances. Entheon Biomedical is investing in research with the aim to commercialize a portfolio of entheogen based therapeutic products for the treatment of addictive disorders.
Entheon Biomedical seeks to research, develop, patent, and distribute psilocybin and DMT based medicines and treatments for those suffering from substance-abuse disorders.This under-serviced market was valued at US$ 13.22 Billion in 2016, and is expected to grow to US$ 27.91 Billion by 2025.